¸ðÀ¼ËØÊ·¿Ë£¨GSK£©¡¢»ÔÈð£¨Pfizer£©¡¢ÑÎÒ°Ò壨Shionogi£©¹²Í¬³ÉÁ¢µÄHIV/AIDSºÏ×ÊÆóÒµViiV Healthcare 1ÔÂ21ÈÕÐû²¼£¬HIVÐÂÒ©Tivicay£¨dolutegravir£¬50mgƬ¼Á£©»ñÅ·ÃËίԱ»á£¨EC£©Åú×¼£¬ÁªºÏÆäËû¿¹Äæת¼²¡¶¾Ò©ÎïÓÃÓÚHIV³ÉÈ˸ÐȾÕߺÍ12ËêÒÔÉÏÇàÉÙÄê¸ÐȾÕßµÄÖÎÁÆ¡£
TivicayµÄ»ñÅú£¬ÊÇ»ùÓÚ4¸ö¹Ø¼üÐÔIIIÆÚÁÙ´²ÊÔÑ飨SPRING-2¡¢SINGLE¡¢SAILING¡¢VIKING-3£©µÄ°²È«ÐÔºÍÁÆЧÊý¾Ý¡£
TivicayÒÑÓÚ2013Äê8Ô»ñFDAÅú×¼£¬²¢ÓÚ2013Äê10Ô»ñ¼ÓÄôóÎÀÉú²¿Åú×¼£¬ÁªºÏÆäËû¿¹Äæת¼²¡¶¾ÖƼÁ£¬ÓÃÓÚ¼ÈÍùÒÑÖÎÁƹý¡¢»ò³õÖÎHIV-1³ÉÈ˺Í12Ëê¼°ÒÔÉÏÌåÖØÖÁÉÙ40ǧ¿Ë¶ùͯ¸ÐȾÕß¡£
´ËÇ°£¬¶ÀÁ¢·ÖÎö¹«Ë¾Datamonitor Healthcare·¢²¼±¨¸æÖ¸³ö£¬TivicayÈô»ñÅ·ÃËÅú×¼£¬±Ø½«¶ÔÈ«ÇòHIVÊг¡²úÉú¾Þ´óµÄÓ°Ï죬µ½2016Ä꣬Tivicay±Ø½«³ÉΪHIVÖÎÁƵÄÖ÷Á÷ÕûºÏøÒÖÖƼÁ¡££¨Ïê¼û¡¶2022ÄêÈ«ÇòHIVÊг¡½«´ï168ÒÚÃÀÔª¡·£©
ÔÚÁÙ´²ÊÔÑéÖУ¬TivicayÁÆЧÓÅÓÚÇ¿Éú£¨JNJ£©µÄµ°°×øÒÖÖƼÁPrezista£¨darunavir£¬µØÈðÄÇΤ£©£¬Í¬Ê±Ó뵱ǰµÄ±ê×¼»¤ÀíÒ©ÎïÕûºÏøÒÖÖƼÁIsentress£¨raltegravir£¬ÀÌæÀΤ£©ÁÆЧÏ൱¡£IsentressÓÉĬɳ¶«£¨Merck & Co£©¿ª·¢¡£
Datamonitor Healthcare·ÖÎöʦJoseph Hedden³Æ£¬TivicayÓëÆäËûһЩ¾ºÕùÒ©Îﲻͬ£¬¸ÃÒ©²»ÐèÒªÓëÒ©Îï´Ù½ø¼ÁÁªºÏÓÃÒ©£¬Í¬Ê±Ò²¾ßÓÐÒ»¸ö·Ç³£ÓÐÎüÒýÁ¦µÄÄÍÒ©ÊôÐÔ¡£ÔÚ½ÓÏÂÀ´¼¸ÄêÀÒÔÕûºÏøÒÖÖƼÁÏúÊÛ¶î¼ÆË㣬ÕâЩÊôÐÔ½«Íƶ¯TivicayÖÁÅÅÃûµÚÒ»µÄλÖá£
TivicayΪÿÈÕÒ»´ÎµÄ¿Ú·þÒ©ÎÊÇHIVÕûºÏøÒÖÖƼÁ£¬Ö¼ÔÚÓëÆäËû¿¹Äæת¼²¡¶¾ÖƼÁÁªºÏÓÃÓÚ¼ÈÍùÒÑÖÎÁƹý¡¢»ò³õÖÎHIV-1³ÉÈ˺Í12Ëê¼°ÒÔÉÏÌåÖØÖÁÉÙ40ǧ¿Ë¶ùͯ¸ÐȾÕß¡£
SPRING-2£ºÔÚ822ÀýHIV¸ÐȾÕßÖпªÕ¹£¬ÆÀ¼ÛÁËÿÌì1´ÎTivicayÓëÿÌì2´Îraltegravir£¨ÀÌæÀΤ£©ÓëÒ»Ö̶ֹ¨¼ÁÁ¿Ë«NRTIÁÆ·¨ÁªºÏÖÎÁƵÄÁÆЧ¡£48ÖÜʱ£¬º¬Tivicay·½°¸ÓÐ88%µÄ»¼ÕßʵÏÖ²¡¶¾Ñ§ÒÖÖÆ£¨HIV-1 RNA<50 c/ml£©£¬º¬raltegravir·½°¸Îª86%£¬´ïµ½ÁË10%µÄ·ÇÁÓÐÔ±ê×¼¡£
SINGLE£ºÔÚ833Àý³õÖÎHIV¸ÐȾÕßÖпªÕ¹£¬ÆÀ¼ÛÁËÿÌì1´ÎTivicay+°¢°Í¿¨Î¤/ÀÃ×·ò¶¨Ïà¶ÔÓÚµ¥Ò»Æ¬¼ÁAtriplaµÄÁÆЧ¡£48ÖÜʱ£¬º¬Tivicay·½°¸ÓÐ88%µÄ»¼ÕßʵÏÖ²¡¶¾Ñ§ÒÖÖÆ£¨HIV-1 RNA<50 c/ml£©£¬Atripla·½°¸Îª81%£¬Êý¾Ý¾ßÓÐͳ¼ÆѧÏÔ×ŲîÒì¡£Tivicay·½°¸×éÓÐ2%»¼ÕßÒò²»Á¼Ê¼þÖÐÖ¹ÖÎÁÆ£¬Atripla·½°¸×éΪ10%¡£
SAILING£ºÔÚ719Àý¾µ±Ç°ÁÆ·¨ÖÎÁÆʧ°Üµ«Î´Ê¹ÓÃÕûºÏøÒÖÖƼÁÖÎÁƵĻ¼ÕßÖпªÕ¹£¬ÆÀ¼ÛÁËÿÌì1´ÎTivicayºÍÿÌì2´Îraltegravir£¨ÀÌæÀΤ£©½áºÏÒ»ÖÖ±³¾°·½°¸£¨2ÖÖÖƼÁ£¬ÆäÖÐÖÁÉÙ1ÖÖÍêÈ«»îÐÔ¼Á£©µÄÁÆЧ¡£24ÖÜʱ£¬º¬Tivicay·½°¸ÓÐ79%µÄ»¼ÕßʵÏÖ²¡¶¾Ñ§ÒÖÖÆ£¨HIV-1 RNA<50 c/ml£©£¬º¬raltegravir·½°¸Îª70%£¬Êý¾Ý¾ßÓÐͳ¼ÆѧÏÔ×ŲîÒì¡£
VIKING-3£ºÔÚ183ÀýÕýÔÚ½ÓÊÜÖÎÁÆ¡¢ÇÒHIVÒѶÔÊýÀàHIVÒ©Î°üÀ¨ÕûºÏøÒÖÖƼÁÀ×ÌظñΤºÍ/»òelvitegravir£©µÄ³ÉÈ˸ÐȾÕßÖпªÕ¹¡£¸ÃÏîÑо¿ÖУ¬±³¾°·½°¸ÖÐÌí¼ÓTivicayÖÎÁÆ7Ììºó£¬HIV RNAˮƽϽµ´ï1.4 log10 c/ml¡£24ÖÜʱ£¬Ìí¼ÓTivicay·½°¸ÓÐ63%µÄ»¼ÕßʵÏÖ²¡¶¾Ñ§ÒÖÖÆ£¨HIV-1 RNA<50 c/ml£©¡£
TivicayÓÃÓÚ12Ëê¼°ÒÔÉÏ¡¢ÌåÖØÖÁÉÙ40ǧ¿Ë¶ùͯµÄÊÊÓ¦Ö¢ÉêÇ룬ÊÇ»ùÓÚÒ»Ïî¶àÖÐÐÄ¡¢¿ª·¢±êÇ©ÊÔÑéµÄ°²È«ÐÔ¡¢Ò©´ú¶¯Á¦Ñ§¡¢Ò©Ð§ÆÀ¼ÛÊý¾Ý¡£¸ÃÏîÑо¿ÔÚ¼ÈÍùδ½ÓÊܹýÕûºÏøÒÖÖƼÁÖÎÁƵĻ¼ÕßÖпªÕ¹¡£
ViiVÒ½ÁƱ£½¡¹«Ë¾ÊǸðÀ¼ËØÊ·¿Ë£¨GSK£©ºÍ»ÔÈð£¨Pfizer£©ÓÚ2009ÄêÁªºÏ³ÉÁ¢µÄHIV/AIDSÒ©ÎïÑз¢¹«Ë¾£¬Ä¿Ç°£¬GSK³ÖÓÐViiV 76.5%µÄ¹É·Ý£¬»ÔÈð³ÖÓÐ10%µÄ¹É·Ý£¬ÈÕ±¾ÑÎÒ°Ò壨Shionogi£©³ÖÓÐ10%µÄ¹É·Ý¡£
|